Mirvetuximab Soravtansine Offers New Path Forward for Patients with Frα-Positive Platinum-Resistant Ovarian CancerMarch 13th 2023
Kathleen Lutz, RN, NP-BC WH, weighs in on the recent approval of mirvetuximab soravtansine-gynx for patients with folate receptor alpha (Frα)-positive, platinum-resistant ovarian cancer.
Vaginal/Vulvar Symptoms Show Improvement With Lasofoxifene in Postmenopausal Women With ER+/HER2–, ESR1-Mutated Breast Cancer
Lasofoxifene may be helpful in managing vaginal/vulvar symptoms in women with estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.
Remote Patient Monitoring for CAR T Demonstrates Feasibility in the Outpatient SettingMarch 10th 2023
During the 2023 Tandem Meeting, Trista Carelock RN, BSN, ONC, BMT-CN, highlighted how her institution leveraged remote patient monitoring to offer outpatient CAR T-cell therapy to patients.
ODAC Votes in Favor Of Polatuzumab Vedotin in Patients With Treatment Naïve LBCLMarch 10th 2023
The FDA’s Oncologic Drugs Advisory Committee voted 11 to 2 in support of the benefit-risk profile displayed by polatuzumab vedotin-piiq in patients with previously untreated large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified.
Opinion: Clear Communication Is A Form Of Patient AdvocacyMarch 9th 2023
We can help our patients feel supported is by providing them with clear information about their treatment plan and what to expect. By doing so, we empower them to take control of their own health.
RWD Support Palbociclib Plus Aromatase Inhibitor Therapy for Elderly Patients With HR+/HER2– Metastatic Breast CancerMarch 7th 2023
Data from a retrospective analysis confirm the benefit of palbociclib plus an aromatase inhibitor in elderly patients with hormone receptor–positive, HER2-negative advanced/metastatic breast cancer.
Smith Discusses Importance of Adherence When Integrating Pirtobrutinib Into Clinical PracticeMarch 7th 2023
Leslie Smith, DNP, RN, APRN-CNS, BMTCN, AOCNS, highlights the pirtobrutinib approval for mantle cell lymphoma, and what she anticipates will encompass best nursing practices with the newly approved agent.
Savolitinib Plus Durvalumab Induces High Response Rates in MET-Driven Papillary Renal CancerMarch 4th 2023
A combination of immune checkpoint inhibitor and MET-targeted therapy led to high responses in patients with MET-driven papillary renal cancer, although the regimen missed its primary end point.
Abemaciclib Indication Expands to Include HR+, HER2–, Node+, High-Risk, Early Breast CancerMarch 3rd 2023
Abemaciclib, in combination with endocrine therapy, had been approved as an adjuvant treatment for patients with high-risk, hormone receptor–positive, HER2-negative, node-positive, early breast cancer.